Clinical Trials in Myeloproliferative Neoplasms (MPN)

 

Target mechanism of investigative drug

 

Title of clinical trial

 

Hyperlink

 

PHAZAR

 

This trial is for people with advanced myeloproliferative neoplasms that include thrombocythaemia, polycythaemia vera or myelofibrosis.

 

 

PAC203

 

This is a trial for patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis previously Treated with Ruxolitinib

 

 

ABBVIE NAVITOCLAX

 

A phase 2 study looking at the addition of Navitoclax, for patients with myelofibrosis who currently take Ruxolitinib.